US based FDNA, a leader in artificial intelligence and precision medicine, has announced the launch of Face2Gene LABS as part of a broader collaboration with PerkinElmer, Inc., a global leader committed to innovating for a healthier world.

Together, they will offer genomic services paired with next-generation phenotyping (NGP) technologies for more efficient and accurate diagnoses.

By combining FDNA’s artificial intelligence-based technologies and services with PerkinElmer’s longstanding diagnostics expertise and state-of-the-art clinical genomics program, Face2Gene LABS will give clinicians access to:

• FDNA’s unprecedented phenotypic and genotypic data associated with more than 10,000 diseases from over 150,000 patients around the world;
• PerkinElmer Genomics’ global laboratory network and extensive database of known genetic variations from different ancestries around the world;
• Improved test selection, gene targeting, and variant prioritization through the integration of NGP technologies into molecular analysis, while reducing time spent and lowering testing costs;
• ISO 27001 certified platform that facilitates secure communication of patient information between clinicians and labs.